InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.260 0.06 (2.59%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,941 Response to ASX price query 8 Apr 2014 9:56AM $4.960 $2.260 fallen by 54.44%
$2,941 Half Yearly Report and Accounts 26 Feb 2014 8:27AM $5.970 $2.260 fallen by 62.14%
$2,941 Key European Patent Granted for Mesoblast's MPCs 20 Feb 2014 9:37AM $5.790 $2.260 fallen by 60.97%
$2,941 Appendix 4C - quarterly 31 Jan 2014 4:40PM $5.880 $2.260 fallen by 61.56%
$2,941 Positive Disc Repair Results Using Mesoblast Stem Cells 30 Jan 2014 8:28AM $5.800 $2.260 fallen by 61.03%
$2,941 Mesoblast Reports Positive Type 2 Diabetes Trial Results 4 Dec 2013 10:36AM $6.160 $2.260 fallen by 63.31%
$2,941 New Japanese Regenerative Medicine Legislation 25 Nov 2013 10:00AM $6.020 $2.260 fallen by 62.46%
$2,941 MPCs Strengthen Cardiac Function in End-Stage Heart Failure 19 Nov 2013 9:21AM $5.950 $2.260 fallen by 62.02%
$2,941 Improved Survival in Children with GvHD After Cell Therapy 14 Nov 2013 10:34AM $6.150 $2.260 fallen by 63.25%
$2,941 MPCs Induce Functional Recovery in Ischemic Stroke Model 11 Nov 2013 9:56AM $6.270 $2.260 fallen by 63.96%
$2,941 FDA Clears Phase 3 Heart Failure Trial 31 Oct 2013 9:02AM $6.600 $2.260 fallen by 65.76%
$2,941 MSBs Registration Plans for GVHD Cell Product in Japan 28 Oct 2013 10:12AM $5.970 $2.260 fallen by 62.14%
$2,941 Appendix 4C - quarterly 25 Oct 2013 4:48PM $5.890 $2.260 fallen by 61.63%
$2,941 Mesoblast, Intrexon and Ziopharm to Target Cancers 24 Oct 2013 8:31AM $5.960 $2.260 fallen by 62.08%
$2,941 Mesoblast Acquires Osiris' Cultured Stem Cell Business 11 Oct 2013 10:08AM $5.820 $2.260 fallen by 61.17%
$2,941 Preliminary Final Report 29 Aug 2013 11:48AM $5.470 $2.260 fallen by 58.68%
$2,941 Appendix 4C - quarterly 1 Aug 2013 8:24AM $5.870 $2.260 fallen by 61.50%
$2,941 MSB Receives $4.3M Pipeline Funds from Australian Government 18 Jul 2013 9:30AM $5.670 $2.260 fallen by 60.14%
$2,941 MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy 26 Jun 2013 10:47AM $5.420 $2.260 fallen by 58.30%
$2,941 Key Mesenchymal Precursor Cell Patent Granted in Japan 5 Jun 2013 9:46AM $6.130 $2.260 fallen by 63.13%
$2,941 Circulation Research Publishes AMI Preclinical Trial Results 15 May 2013 9:47AM $5.580 $2.260 fallen by 59.50%
$2,941 Appendix 4C - quarterly 30 Apr 2013 2:31PM $5.880 $2.260 fallen by 61.56%
$2,941 POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL FOR DISC REPAIR 22 Apr 2013 1:02PM $5.490 $2.260 fallen by 58.83%
$2,941 Mesoblast Enters into Agreements to Raise A$170million 6 Mar 2013 10:03AM $6.450 $2.260 fallen by 64.96%
$2,941 Trading Halt 4 Mar 2013 10:12AM $6.440 $2.260 fallen by 64.91%

1001 - 1025 of 1201 results

Page 41 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.